(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2014 (18.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/144903 A1

(51) International Patent Classification:
A61K 38/18 (2006.01) *C07K 14/00* (2006.01)
A61K 38/00 (2006.01)

(21) International Application Number:
PCT/US2014/029502

(22) International Filing Date:
14 March 2014 (14.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/799,928 15 March 2013 (15.03.2013) US

(71) Applicants: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). **PINTA BIOTHERAPEUTICS, INC.** [US/US]; 3260 Bayshore Blvd., Brisbane, CA 94005 (US).

(72) Inventors: **PADHI, Desmond**; C/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). **HAN, Huiquan**; C/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). **HAQQ, Christopher, Michael**; C/o Pinta Biotherapeutics, Inc., 3260 Bayshore Blvd., Brisbane, CA 94005 (US). **CIECHANOVER, Isaac**; C/o Pinta Biotherapeutics, Inc., 3260 Bayshore Blvd., Brisbane, CA 94005 (US).

(74) Agents: **HUBL, Susan T.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, California 94041 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: MYOSTATIN ANTAGONISM IN HUMAN SUBJECTS




Fig.13

(57) Abstract: Disclosed are methods of treating or modulating cachexia and/or increasing lean body mass and/or increasing lower extremity muscle size in a prostate cancer patient comprising administering a therapeutically effective amount of a myostatin antagonist. Further disclosed is the peptibody sequence of the myostatin antagonist, and the formulation of the peptibody.

WO 2014/144903 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*